Many women in perimenopause and menopause report stubborn weight gain around the abdomen (“menopause belly”), despite diet and exercise. This is driven by hormonal changes, reduced oestrogen, increased insulin resistance and altered fat distribution. Recent research suggests that combining menopausal hormone therapy (MHT/HRT) with GLP-1 receptor agonist medications (such as Wegovy, Ozermpic or Mounjaro) can enhance weight-loss results. This blog explores how the combination works, the evidence and how to approach it safely.
Why Weight Gain Happens in Menopause
As oestrogen levels decline, fat distribution shifts from hips and thighs to the abdomen. Metabolism slows, muscle mass falls, and insulin sensitivity worsens. These changes increase the risk of type 2 diabetes and cardiovascular disease. PCCA Patients+1
What Are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) receptor agonists such as semaglutide and tirzepatide reduce appetite, slow gastric emptying and improve insulin response. They are approved in the UK for weight management under specific criteria. British Menopause Society+1
Why the Combination with HRT Makes Sense
Women using HRT plus GLP-1 have shown greater weight loss compared with GLP-1 alone. A study of postmenopausal women found about 30% greater total body weight loss in those on both therapies. PCCA Patients+1 Hormone therapy may enhance fat loss by improving metabolic flexibility and enabling the body to respond better to appetite-suppressing drugs.
Safety & Practical Guidance
The combination is promising but requires careful management:
- Use transdermal oestrogen rather than oral, as GLP-1 slows gastric emptying and may reduce absorption of oral hormones. British Menopause Society+1
- Ensure adequate endometrial protectin is maintained particularly if using oral progestogen therapy as part of HRT for this as absorption can be impacted
- Monitor VTE risk, cardiovascular status, and ensure comprehensive lifestyle support.
- Ensure GLP-1 is prescribed via weight-management specialist services and the dose is adjusted with MHT in mind.
How to Implement the Plan
- Begin with lifestyle optimisation: good protein intake, resistance training, quality sleep and stress management.
- Review for menopausal symptoms, and if appropriate, initiate HRT/MHT.
- If weight is not responding, discuss GLP-1 options with a specialist doctor.
- Use transdermal hormone preparations and coordinate timing of medications.
- Monitor progress at 3-, 6- and 12-month intervals (weight, metabolic markers, quality of life).
Support at The Menopause Medic
In Berkhamsted, St Albans and remotely beyond Hertfordshire, The Menopause Medic offers tailored programmes combining hormone care and metabolic strategies for midlife women.
References
- British Menopause Society Tool: Use of incretin-based therapies in women using HRT: https://thebms.org.uk/wp-content/uploads/2025/05/23-BMS-TfC-Use-of-incretin-based-therapies-APRIL2025-E.pdf British Menopause Society
- PCCARx article: Managing menopausal weight gain – role of oestrogen and GLP-1: https://patients.pccarx.co.uk/managing-menopausal-weight-gain-the-role-estrogen-plays-with-glp-1-agonists/ PCCA Patients
- GLP-1 Health article: Study shows HRT boosts GLP-1 drug effectiveness: https://www.glp1health.com/post/menopause-hormone-therapy-supercharges-glp-1-weight-loss-drugs GLP